Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Phase I Trial of Ibrutinib, Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Sikander Ailawadhi, MD, Aneel Paulus, MD, Victoria R. Alegria, Betsy Laplant, MS, Muhamad Alhaj Moustafa, MD, Dustin Chapin, Keisha Jackson, Prachi Jani, MD, Salman Ahmed, MD, Brett Edwards, Alak Manna, PhD, Vivek Roy, MD, Taimur Sher, MD, Asher A. Chanan-Khan, MD

Blood (2019) 134 (Supplement_1): 1912.

https://doi.org/10.1182/blood-2019-128233

Published: 2019

Journal Articles

Phase I Study of a Novel Bcl-2 Inhibitor, at-101 in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Sikander Ailawadhi, MD, Victoria R. Alegria, Salman Ahmed, MD, Betsy Laplant, MS, Alak Manna, PhD, Ricardo Parrondo, MD, Vivek Roy, MD, Taimur Sher, MD, Brett Edwards, Stephanie Lanier, Keisha Jackson, Asher A. Chanan-Khan, MD, Aneel Paulus, MD

Blood (2019) 134 (Supplement_1): 3137.

https://doi.org/10.1182/blood-2019-128610

Published: 2019

Journal Articles

Comparative Analysis on the Anti-Tumor Activity of Venetoclax and Obinutuzumab (VO) Versus Venetoclax and Rituximab (VR) in Primary CLL Cells, Ex Vivo

Madiha Iqbal, MBBS, Aarushi Sharma, Alak Manna, PhD, Sharoon Akhtar, MPhil, Taimur Sher, MD, Asher A. Chanan-Khan, MD, Sikander Ailawadhi, Aneel Paulus, MD

Blood (2018) 132 (Supplement 1): 5558.

https://doi.org/10.1182/blood-2018-99-120188

Published: 2018

Journal Articles

Computational Modelling of Multiple Myeloma Patient Genomic Signatures to Predict Treatment Outcome

Aneel Paulus, MD, Prachi Jani, MD, Salman Ahmed, MD, Sonikpreet Aulakh, MD, Alak Manna, PhD, Neeraj Kumar Singh, B.Tech, Mohammed Sauban, B.E, Zakir Husain, M.Tech, Ansu Kumar, M.Sc., Pallavi Kumari, M.Sc., Anuj Tyagi, M.Sc., Taimur Sher, MD, Rami Manochakian, MD, Vivek Roy, MD, Taher Abbasi, MS, MBA, Shireen Vali, PhD, Asher A. Chanan-Khan, MD, Sikander Ailawadhi

Blood (2018) 132 (Supplement 1): 1911.

https://doi.org/10.1182/blood-2018-99-119574

Published: 2018

Journal Articles

The Oral Proteasome Inhibitor Ixazomib, Alone and in Combination with Ibrutinib, Induces Lethality in Waldenstrom Macroglobulinemia Cells That Are Resistant to Ibrutinib

Aneel Paulus, MD, Alak Manna, PhD, Sharoon Akhtar, MPhil, Neeraj Kumar Singh, B.Tech, Ansu Kumar, MS, Kabya Basu, MS, Akshita Trivedi, B.Tech, Debapriya Majumdar, M.Sc., Taher Abbasi, MS, MBA, Shireen Vali, PhD, Vivek Roy, MD, Peter Martin, FRCPC, MD MS, Morton Coleman, MD, Anne J Novak, PhD, Stephen M Ansell, MD PhD, Sikander Ailawadhi, Asher A. Chanan-Khan, MD

Blood (2017) 130 (Supplement 1): 1260.

https://doi.org/10.1182/blood.V130.Suppl_1.1260.1260

Published: 2017

Journal Articles

Comparative Analysis of Gene Expression Status to Predict Response to Initial Multiple Myeloma Treatment: Utility of the Mmrf Commpass Database in Validating Historical Findings

Aneel Paulus, MD, Marie Coignet, Alak Manna, PhD, Mayank Sharma, Taimur Sher, MD, Vivek Roy, MD, Asher A. Chanan-Khan, MD, Sikander Ailawadhi

Blood (2017) 130 (Supplement 1): 2178.

https://doi.org/10.1182/blood.V130.Suppl_1.2178.2178

Published: 2017

Journal Articles

PSMB9 Mediates Resistance to Bortezomib in Multiple Myeloma

Aneel Paulus, MD, Sharoon Akhtar, MPhil, Thomas Caulfield, Alak Manna, PhD, Vivek Roy, MD, Sikander Ailawadhi, Asher A. Chanan-Khan, MD

Blood (2017) 130 (Supplement 1): 3836.

https://doi.org/10.1182/blood.V130.Suppl_1.3836.3836

Published: 2017

Journal Articles

Daratumumab Mitigates B-Cell Receptor Signaling and Enhances Antitumor Activity of Ibrutinib in Chronic Lymphocytic Leukemia (CLL) Cells

Alak Manna, PhD, Sharoon Akhtar, MPhil, Zahara Meghji, Kirtipal Bhatia, Paul Yi, BS, Sameer A. Parikh, MD, Wei Ding, MD PhD, Jose F. Leis, MD PhD, Taimur Sher, MD, Fabio Malavasi, MD, Victoria R. Alegria, Sikander Ailawadhi, Asher A. Chanan-Khan, MD, Aneel Paulus, MD

Blood (2017) 130 (Supplement 1): 3019.

https://doi.org/10.1182/blood.V130.Suppl_1.3019.3019

Published: 2017

Journal Articles

Targeting CD38 with Daratumumab Suppresses B-Cell Receptor Signaling and Enhances the Activity of Ibrutinib in Waldenstrom Macroglobulinemia Cells

Aneel Paulus, MD, Alak Manna, PhD, Sharoon Akhtar, MPhil, Taimur Sher, MD, Vivek Roy, MD, Morton Coleman, MD, Anne J Novak, PhD, Stephen M Ansell, MD PhD, Fabio Malavasi, MD, Sikander Ailawadhi, Asher A. Chanan-Khan, MD

Blood (2017) 130 (Supplement 1): 1529.

https://doi.org/10.1182/blood.V130.Suppl_1.1529.1529

Published: 2017

Journal Articles

Daratumumab Decreases Treg-Mediated Immunosuppression and Potentiates CD8+ T-Cell-Induced Killing of Chronic Lymphocytic Leukemia (CLL) Cells Ex Vivo

Alak Manna, PhD, Sharoon Akhtar, MPhil, Paul Yi, BS, Sameer A. Parikh, MD, Wei Ding, MD PhD, Jose F. Leis, MD PhD, Victoria R. Alegria, Taimur Sher, MD, Fabio Malavasi, MD, Sikander Ailawadhi, Asher A. Chanan-Khan, MD, Aneel Paulus, MD

Blood (2017) 130 (Supplement 1): 1736.

https://doi.org/10.1182/blood.V130.Suppl_1.1736.1736

Published: 2017

NARROW

Phase I Trial of Ibrutinib, Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Phase I Study of a Novel Bcl-2 Inhibitor, at-101 in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Comparative Analysis on the Anti-Tumor Activity of Venetoclax and Obinutuzumab (VO) Versus Venetoclax and Rituximab (VR) in Primary CLL Cells, Ex Vivo

Computational Modelling of Multiple Myeloma Patient Genomic Signatures to Predict Treatment Outcome

The Oral Proteasome Inhibitor Ixazomib, Alone and in Combination with Ibrutinib, Induces Lethality in Waldenstrom Macroglobulinemia Cells That Are Resistant to Ibrutinib

Comparative Analysis of Gene Expression Status to Predict Response to Initial Multiple Myeloma Treatment: Utility of the Mmrf Commpass Database in Validating Historical Findings

PSMB9 Mediates Resistance to Bortezomib in Multiple Myeloma

Daratumumab Mitigates B-Cell Receptor Signaling and Enhances Antitumor Activity of Ibrutinib in Chronic Lymphocytic Leukemia (CLL) Cells

Targeting CD38 with Daratumumab Suppresses B-Cell Receptor Signaling and Enhances the Activity of Ibrutinib in Waldenstrom Macroglobulinemia Cells

Daratumumab Decreases Treg-Mediated Immunosuppression and Potentiates CD8+ T-Cell-Induced Killing of Chronic Lymphocytic Leukemia (CLL) Cells Ex Vivo

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only